Novo Nordisk (NOVA) Stock Statistics & Valuation Metrics

Novo Nordisk has a market cap or net worth of $181.05B. The enterprise value is €257.56B.

Novo Nordisk has 3,390,128,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Novo Nordisk’s return on equity (ROE) is 0.70 and return on invested capital (ROIC) is 38.99%.

The current PE Ratio of Novo Nordisk is 13.2. Novo Nordisk’s PEG ratio is 1.28.

In the last 12 months, Novo Nordisk had revenue of 290.40B and earned 100.99B in profits. Earnings per share was 22.67.

In the last 12 months, operating cash flow was 123.78B and capital expenditures -61.05B, giving a free cash flow of 62.74B billion.

Novo Nordisk pays an annual dividend of ―, resulting in a dividend yield of ―

Novo Nordisk upcoming earnings date is Feb 4, 2026, Before Open (Confirmed).

Novo Nordisk as a current ratio of 0.74, with Debt / Equity ratio of 59.06%

In the past 12 months, Novo Nordisk has paid 26.20B in taxes.

Novo Nordisk EV to EBITDA ratio is 20.72, with an EV/FCF ratio of 40.87.

Novo Nordisk has $32.58B in cash and marketable securities with $101.21B in debt, giving a net cash position of -$68.63B billion.

Gross margin is 83.95%, with operating margin of 44.19%, and net profit margin of 34.78%.

The average price target for Novo Nordisk is $49.81, which is 11.43% higher than the current price. The consensus rating is Moderate Buy